Semaglutide vs Tirzepatide: Efficacy, Side Effects, and Cost
You have probably seen both medications mentioned online – sometimes interchangeably, sometimes as though one is clearly superior. The research suggests a more nuanced picture. Both medications work. Tirzepatide tends to produce more weight loss. But the right medication for you depends on your health history, cost preference, and what your provider determines is clinically appropriate for your situation.
The mechanism difference: one receptor vs. two
This is the fundamental distinction between the medications, and it is the reason tirzepatide typically produces greater weight loss.
Semaglutide is a GLP-1 receptor agonist. It activates one receptor type, the GLP-1 receptor. This receptor regulates appetite, slows digestion, and affects how your body uses glucose. It is a powerful target.
Tirzepatide is a GLP-1/GIP receptor agonist. It activates two receptors: the GLP-1 receptor (same as semaglutide) and the GIP receptor (glucose-dependent insulinotropic polypeptide). GIP enhances insulin secretion when nutrients are present, and it has separate effects on fat tissue metabolism and appetite signaling. By targeting both receptors, tirzepatide engages two separate biological pathways that influence weight and metabolism.
This dual mechanism is why tirzepatide produces greater weight loss on average. One pathway is effective. Two pathways together appear to be more effective.
That said, this does not mean semaglutide does not work. It works very well for many patients. The question is not “does it work” but rather “which works better, and for whom.”
Weight loss efficacy: what the trials show
The clinical evidence comes from three major trials.
STEP 1: Semaglutide at maximum dose
The STEP 1 trial (published in the New England Journal of Medicine, 2021) studied semaglutide 2.4mg weekly versus placebo over 68 weeks in approximately 1,960 adults with obesity or weight-related conditions. The median weight loss was 14.9% on semaglutide 2.4mg (the maximum weight management dose) versus 2.4% on placebo. Over the trial period, that translated to mean absolute weight loss of approximately 15 pounds on semaglutide. Individual results ranged widely, with some patients losing 30+ pounds and others losing much less.
This was a landmark trial that established semaglutide’s efficacy for weight management. The medication clearly outperformed placebo.
SURMOUNT-1: Tirzepatide at multiple doses
The SURMOUNT-1 trial (published in the New England Journal of Medicine, 2022) studied tirzepatide 5mg, 10mg, and 15mg weekly versus placebo over 72 weeks in approximately 2,500 adults with obesity or weight-related conditions. Mean weight loss was 15% at the 5mg dose, 19.5% at 10mg, and 20.9% at 15mg. Placebo achieved 3.1% weight loss.
The top-line finding: tirzepatide at its maximum dose (15mg) produced approximately 6% greater weight loss than semaglutide at its maximum dose (2.4mg). This is clinically meaningful, though not enormous.
SURMOUNT-5: Head-to-head comparison
This is the most directly relevant trial for your decision. SURMOUNT-5 (published in the New England Journal of Medicine, 2025) compared tirzepatide 10mg and 15mg directly against semaglutide 2.4mg over 68 weeks.
Results:
- Tirzepatide 15mg: mean weight loss 22%
- Tirzepatide 10mg: mean weight loss 21%
- Semaglutide 2.4mg: mean weight loss 15%
Tirzepatide at the highest dose produced approximately 47% greater weight loss than semaglutide at its maximum dose. The difference between tirzepatide 15mg and tirzepatide 10mg was smaller, suggesting that 10mg may be the practical maximum for many patients.
What this means for your choice
Clinical data shows tirzepatide produces greater average weight loss. But using “average” here masks individual variation. For example, some patients on semaglutide could lose more weight than some patients on tirzepatide. Metabolism, genetics, adherence to nutrition and exercise guidance, and unmeasured individual factors all influence outcomes.
Here is the practical interpretation: If you have access to tirzepatide and tolerate it well, it is likely to produce more weight loss. If semaglutide is your starting point and you are responding well to it, there is no urgent need to switch. Cost may be the deciding factor. At Transformation Health, compounded tirzepatide is $339/month and compounded semaglutide is $249/month.
Your provider will also consider your health history. Tirzepatide’s additional mechanism (GIP receptor activation) may provide additional benefit for patients with type 2 diabetes. It may be the better choice for you specifically, independent of the population average.
Side effects: are they different?
Both medications have similar gastrointestinal side effect profiles. Nausea, constipation, diarrhea, and vomiting are common to both, and the reported rates are comparable in clinical trials.
The SURMOUNT-5 head-to-head trial specifically compared tolerability and found no significant differences in the frequency or severity of gastrointestinal adverse events between tirzepatide and semaglutide. Neither medication showed a safety advantage over the other.
Both carry the same black box warning regarding thyroid C-cell tumors observed in animal studies (these have not been reported in humans). Both carry warnings about pancreatitis and gallbladder disease. Both can affect diabetes medications if you are on them.
If you have experienced side effects on one medication, this does not guarantee you will experience the same on the other. Biological tolerance is individual. Some patients who are nauseated on semaglutide tolerate tirzepatide well, and vice versa.
The key to managing side effects with both medications is a gradual dose escalation schedule. Rushing the escalation significantly increases nausea and GI distress. A slower approach allows your body to adjust. Your provider will guide this.
Cost comparison
Transformation Health prices compounded medications all-inclusive. The price covers medication, your provider’s oversight, required lab work (through Quest or Labcorp), and access to medical weight loss coaching.
- Compounded semaglutide: $249/month
- Compounded tirzepatide: $339/month
The $90 monthly difference reflects the underlying cost of the active ingredient. The cost difference is real, and it may influence your choice, especially if cost is a significant factor for your household. Over a year, the difference is approximately $1,080.
Both are eligible for FSA and HSA accounts. Neither is currently compatible with American Express card processing. Cancel anytime. No contracts, no hidden fees, no commitment.
If you are comparing our prices to other telehealth programs, make sure you are seeing the complete cost: medication, provider, labs, and any coaching or support included. Some programs advertise a low monthly price and charge separately for the medication, labs, or provider consultation.
Who might prefer semaglutide?
Cost: If cost is your primary concern and you want to minimize monthly spend, semaglutide is $90/month cheaper.
Prior success: If you have previously used semaglutide and responded well, and you tolerate it without significant side effects, there is no compelling reason to switch.
Medication access: In rare cases, tirzepatide may be in shorter supply or not available through your provider’s pharmacy. Semaglutide is more widely available.
Familiarity: Semaglutide has been used for weight management longer than tirzepatide. If you prefer a medication with a longer clinical track record and more patient experience data, semaglutide fits that description.
Who might prefer tirzepatide?
Maximum weight loss: If your goal is the greatest possible weight loss and you are motivated to escalate the dose as tolerated, tirzepatide is likely to deliver more.
Type 2 diabetes: If you have type 2 diabetes in addition to weight management goals, tirzepatide’s dual mechanism may provide additional metabolic benefit beyond weight loss.
Individual response: You can only know which medication works better for you by trying it. If you start on semaglutide and reach a plateau, switching to tirzepatide is a reasonable option. Conversely, if tirzepatide causes unmanageable side effects, semaglutide is an alternative.
How to decide
The decision should involve you and your provider. Here is what your provider will consider:
- Your specific health history (any prior medication adverse reactions, existing conditions, current medications)
- Your weight loss goals and what would be clinically realistic for you
- Your cost situation and what you can sustain long-term
- Whether you have a stated preference based on research or prior experience
The clinical data is clear: tirzepatide produces more weight loss on average. But both medications are effective. The “best” medication is the one that you will take consistently, that your provider determines is appropriate for your health, and that fits your cost tolerance.
Neither medication is a substitute for nutrition and movement. Both work as part of a program that includes dietary guidance, fitness support, and behavioral coaching. Your Transformation Health program includes all three.
Next steps
If you are trying to choose between the two, the clearest path forward is an eligibility assessment. You will answer questions about your health history, weight and BMI, any existing conditions, and your goals. An independent, licensed provider will review your information and make a clinical recommendation.
That recommendation may be semaglutide, tirzepatide, or neither (if the provider determines you do not meet medical criteria). The provider’s job is to determine what is medically appropriate for you, not to sell you the more expensive option.
If you have already started on one medication and want to understand switching, see the guide on transitioning between semaglutide and tirzepatide. If you want a detailed dosing breakdown for either medication, our dosing reference guides walk through escalation schedules and unit conversions for compounded vials.
Important: Compounded medications are not FDA-approved products. They are prepared by US-based, state-licensed compounding pharmacies and have not been independently evaluated by the FDA for safety, efficacy, or quality. Compounded semaglutide and tirzepatide are not the same products as branded FDA-approved medications. All prescriptions require evaluation by an independent, licensed healthcare provider. Not all patients will qualify. Results vary by individual.